{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:38:35Z","timestamp":1793893115383,"version":"4.8.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41409-018-0236-z","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T11:32:18Z","timestamp":1527161538000},"page":"212-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract"],"prefix":"10.1038","volume":"54","author":[{"given":"Alex","family":"Ganetsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar I.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Mangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria V.","family":"Babushok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Drobyski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Timlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"236_CR1","unstructured":"D\u2019Souza A, Fretham C Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2017. Available at: http:\/\/www.cibmtr.org"},{"key":"236_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296\u2013307.","journal-title":"Blood"},{"key":"236_CR3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/asheducation.V2012.1.251.3798879","volume":"2012","author":"SZ Pavletic","year":"2012","unstructured":"Pavletic SZ, Fowler DH. Are we making progress in GVHD prophylaxis and treatment? Hematol Am Soc Hematol Educ Program. 2012;2012:251\u201364.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"236_CR4","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bbmt.2011.06.012","volume":"18","author":"A Xhaard","year":"2012","unstructured":"Xhaard A, Rocha V, Bueno B, de Latour RP, Lenglet J, Petropoulou A, et al. Steroid-refractory acute GVHD: Lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant. 2012;18:406\u201313.","journal-title":"Biol Blood Marrow Transplant"},{"key":"236_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/bmt.2014.69","volume":"49","author":"C Castilla-Llorente","year":"2014","unstructured":"Castilla-Llorente C, Martin PJ, McDonald GB, Storer BE, Appelbaum FR, Deeg HJ, et al. Prognostic factors and outcomes of severe gastrointestinal graft-vs.-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49:966\u201371.","journal-title":"Bone Marrow Transplant"},{"key":"236_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.bbmt.2003.12.304","volume":"10","author":"PJ Martin","year":"2004","unstructured":"Martin PJ, McDonald GB, Sanders JE, Anasetti C, Appelbaum FR, Deeg HJ, et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2004;10:320\u201327.","journal-title":"Biol Blood Marrow Transplant"},{"key":"236_CR7","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","volume":"1813","author":"J Scheller","year":"2011","unstructured":"Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878\u201388.","journal-title":"Biochim Biophys Acta"},{"key":"236_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.00667","volume":"8","author":"THA Tvedt","year":"2017","unstructured":"Tvedt THA, Ersvaer E, Tveita AA, Bruserud O. Interleukin-6 in allogeneic stem cell transplantation: its possible importance for immunoregulation and as a therapeutic target. Front Immunol. 2017;8:1\u201315.","journal-title":"Front Immunol"},{"key":"236_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2009-01-197178","volume":"114","author":"X Chen","year":"2009","unstructured":"Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood. 2009;114:891\u2013900.","journal-title":"Blood"},{"key":"236_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.CCR-10-1198","volume":"17","author":"I Tawara","year":"2011","unstructured":"Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R, et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res. 2011;17:77\u201388.","journal-title":"Clin Cancer Res"},{"key":"236_CR11","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.bbmt.2011.07.001","volume":"17","author":"WR Drobyski","year":"2011","unstructured":"Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17:1862\u201368.","journal-title":"Biol Blood Marrow Transplant"},{"key":"236_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3109\/10428194.2015.1045896","volume":"57","author":"JV Roddy","year":"2016","unstructured":"Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, et al. Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma. 2016;57:81\u20135.","journal-title":"Leuk Lymphoma"},{"key":"236_CR13","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"236_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.imlet.2011.01.004","volume":"136","author":"D Noguchi","year":"2011","unstructured":"Noguchi D, Wakita D, Ohkuri T, Tajima M, Chamoto K, Kitamura H, et al. Blockade of IL-6-signaling inhibits the pathogenesis of CD4+T cell-mediated lethal graft-versus-host reaction against minor histocompatibility antigen. Immuno Lett. 2011;136:146\u201355.","journal-title":"Immuno Lett"},{"key":"236_CR15","doi-asserted-by":"publisher","first-page":"S389","DOI":"10.1016\/j.bbmt.2015.11.910","volume":"22","author":"S Bhatt","year":"2016","unstructured":"Bhatt S, Schulz G, Towerman A, Hente M, Shenoy S. Tocilizumab for the treatment of steroid refractory acute graft versus host disease: a pediatric experience. Biol Blood Marrow Transplant. 2016;22:S389\u2013S390.","journal-title":"Biol Blood Marrow Transplant"},{"key":"236_CR16","first-page":"595","volume":"15","author":"KS Baker","year":"1995","unstructured":"Baker KS, Allen RD, Roths JB, Sidman CL. Kinetic and organ-specific patterns of cytokine expression in acute graft-versus-host disease. Bone Marrow Transplant. 1995;15:595\u2013603.","journal-title":"Bone Marrow Transplant"},{"key":"236_CR17","doi-asserted-by":"publisher","first-page":"E610","DOI":"10.1002\/ajh.24850","volume":"92","author":"JH Jerkins","year":"2017","unstructured":"Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, et al. Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. Am J Hematol. 2017;92:E610\u2013E611.","journal-title":"Am J Hematol"},{"key":"236_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bbmt.2016.10.009","volume":"23","author":"Y Floisand","year":"2017","unstructured":"Floisand Y, Lundin KEA, Lazarevic V, Kristiansen JD, Osnes LTN, Tjonnfjord GE, et al. Targeting integrin \u03b14\u03b27 in steroid-refractory intestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23:172\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"236_CR19","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1470-2045(14)71017-4","volume":"15","author":"GA Kennedy","year":"2014","unstructured":"Kennedy GA, Varelias A, Vuckovic S, Le Texier L, Gartlan KH, Zhang P, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1\/2 trial. Lancet Oncol. 2014;15:1451\u20139.","journal-title":"Lancet Oncol"},{"key":"236_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2017.183434","volume":"103","author":"WR Drobyski","year":"2018","unstructured":"Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, et al. Tocilizumab, tacrolimus, and methotrexate for the prevention of acute graft versus host disease: Low incidence of lower gastrointestinal tract disease. Haematologica. 2018;103:717\u201327.","journal-title":"Haematologica"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0236-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:12:22Z","timestamp":1684617142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0236-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["236"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0236-z","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,24]]},"assertion":[{"value":"21 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}